Literature DB >> 25385057

Radiologic and laboratory differences in patients with tuberculous and parapneumonic pleural effusions showing non-lymphocytic predominance and high adenosine deaminase levels.

J Lee1, S Y Lee, J K Lim, S S Yoo, S Y Lee, S I Cha, J Y Park, C H Kim.   

Abstract

PURPOSE: Tuberculous pleural effusion (TPE) is characterized by lymphocytic predominance and high adenosine deaminase (ADA) levels. However, TPEs sometimes present non-lymphocytic predominance, and parapneumonic effusion (PPE) often exceeds the cutoff value of ADA for TPE. Thus, the differential diagnosis of cases with pleural fluid (PF) showing non-lymphocytic predominance and high ADA levels is challenging. However, limited data concerning the clinical differences in these patients are available.
METHODS: A retrospective study was conducted on TPE and PPE patients with PF showing non-lymphocytic predominance and ADA levels ≥40 U/L in 2009-2013 in a South Korean tertiary referral hospital. The clinical, laboratory, and computed tomography (CT) findings between the groups were analyzed using multivariate logistic regression to develop a prediction model with independent factors for TPE.
RESULTS: Among 353 patients with TPE, 24 (6.8 %) showed PF with non-lymphocytic predominance and ADA levels of ≥40 U/L. Twenty-eight PPE patients who presented PF findings comparable with those of TPE patients were included in the control group. In the final analysis, PF ADA levels >58 U/L and nodular lung lesions on CT were independent positive predictors, while loculated effusion was an independent negative predictor for TPE. Using the prediction model, a score ≥ +3 provided a sensitivity of 88 %, specificity of 93 %, positive predictive value of 91 %, and negative predictive value of 90 % for TPE.
CONCLUSION: PF ADA levels, nodular lung lesions, and loculated pleural effusion may help differentiate TPE from PPE in patients with PF showing non-lymphocytic predominance and ADA levels ≥40 U/L.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25385057     DOI: 10.1007/s15010-014-0697-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  25 in total

1.  Clinical value of whole-blood interferon-gamma assay in patients with suspected pulmonary tuberculosis and AFB smear- and polymerase chain reaction-negative bronchial aspirates.

Authors:  Jaehee Lee; Shin Yup Lee; Seung Soo Yoo; Seung Ick Cha; Dong Il Won; Jae Yong Park; Won-Kil Lee; Chang Ho Kim
Journal:  Diagn Microbiol Infect Dis       Date:  2012-04-26       Impact factor: 2.803

2.  Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication.

Authors:  Dae-Hee Han; Jae-Woo Song; Hee-Soon Chung; Jae-Ho Lee
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

3.  HRCT and whole-blood interferon-gamma assay for the rapid diagnosis of smear-negative pulmonary tuberculosis.

Authors:  Hye-Min Lee; Jong Wook Shin; Jae Yeol Kim; In Won Park; Byoung Whui Choi; Jae Chol Choi; Jae Seung Seo; Chan Woong Kim
Journal:  Respiration       Date:  2010-01-21       Impact factor: 3.580

Review 4.  Diagnosis and treatment of tuberculous pleural effusion in 2006.

Authors:  Arun Gopi; Sethu M Madhavan; Surendra K Sharma; Steven A Sahn
Journal:  Chest       Date:  2007-03       Impact factor: 9.410

5.  Role of common investigations in aetiological evaluation of exudative pleural effusions.

Authors:  Arnab Maji; Malay Kumar Maikap; Debraj Jash; Kaushik Saha; Abhijit Kundu; Debabrata Saha; Sourindranath Banerjee; Anupam Patra
Journal:  J Clin Diagn Res       Date:  2013-09-16

6.  Can tuberculous pleural effusions be diagnosed by pleural fluid analysis alone?

Authors:  S A Sahn; J T Huggins; M E San José; J M Álvarez-Dobaño; L Valdés
Journal:  Int J Tuberc Lung Dis       Date:  2013-06       Impact factor: 2.373

7.  Predictive factors for tuberculosis in patients with a TB-PCR-negative bronchial aspirate.

Authors:  C H Kim; J K Lim; S Y Lee; D I Won; S I Cha; J Y Park; W K Lee; J Lee
Journal:  Infection       Date:  2013-01-03       Impact factor: 3.553

Review 8.  Tuberculous pleural effusion.

Authors:  José M Porcel
Journal:  Lung       Date:  2009-08-13       Impact factor: 2.584

Review 9.  Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis.

Authors:  Qiu-Li Liang; Huan-Zhong Shi; Ke Wang; Shou-Ming Qin; Xue-Jun Qin
Journal:  Respir Med       Date:  2008-01-28       Impact factor: 3.415

10.  High resolution computed tomographic findings in pulmonary tuberculosis.

Authors:  O N Hatipoğlu; E Osma; M Manisali; E S Uçan; P Balci; A Akkoçlu; O Akpinar; C Karlikaya; C Yüksel
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

View more
  4 in total

1.  Pleural fluid adenosine deaminase/serum C-reactive protein ratio for the differentiation of tuberculous and parapneumonic effusions with neutrophilic predominance and high adenosine deaminase levels.

Authors:  Jaehee Lee; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Chang Ho Kim
Journal:  Infection       Date:  2016-08-03       Impact factor: 3.553

2.  Repeatability of pleural adenosine deaminase measurements in diagnostic evaluation of pleural effusions.

Authors:  Ourania S Kotsiou; Panagiota Tzortzi; Rafailia A A Beta; Athanasios Kyritsis; Konstantinos I Gourgoulianis
Journal:  J Clin Lab Anal       Date:  2017-12-07       Impact factor: 2.352

3.  Loculated Tuberculous Pleural Effusion: Easily Identifiable and Clinically Useful Predictor of Positive Mycobacterial Culture from Pleural Fluid.

Authors:  Yousang Ko; Changhwan Kim; Boksoon Chang; Suh-Young Lee; So Young Park; Eun-Kyung Mo; Su Jin Hong; Myung Goo Lee; In Gyu Hyun; Yong Bum Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-12-30

4.  The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions.

Authors:  Jinlin Wang; Jun Liu; Xiaohong Xie; Panxiao Shen; Jianxing He; Yunxiang Zeng
Journal:  BMC Pulm Med       Date:  2017-12-04       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.